Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy delivered with a multi-directional nebulizer (MDN-PIPAC)

• Conditions: C48.2; Peritoneum, unspecified

• Registration Number: DRKS00033077
• Lead Sponsor: Klinikum Dortmund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-10-01
• Study Start: 2023-11-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

All patients who had the chemotherapy drugs administered into the abdominal cavity with the MDN device (multi-directional nebulizer) as part of a PIPAC treatment for peritoneal carcinosis at Klinikum Dortmund between 2022 and 2023.

Exclusion Criteria

Patients who objected to retrospective data analysis.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective observation of perioperative mortality after PIPAC applications with the MDN device

Secondary Outcome Measures

Name	Time	Method
Retrospective observation of morbidity and complications according to Clavien-Dindo after PIPAC applications with the MDN device